A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0

作者：

Kelly, William Kevin ^{[1
]}

Hussain, Arif ^{[2
]}

Saraiya, iren ^{[3
]}

Thanigaimani, Pradeep ^{[4
]}

Sun, Furong

Seebach, Frank A.

Lawy, Israel

Sandigursky, Sabina

Miller, Elizabeth

机构：

[1] Thomas Jefferson Univ, Philadelphia, PA USA

[2] Univ Maryland, Med Ctr, Baltimore, MD USA

[3] Rutgers State Universityof New Jersey, Canc Inst New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA

[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 6_SUPPL期

关键词：

283-2494-5577-2829; 613-225-325; 261-566-9263; 283-224-11611-3642-3956; 283-197-6219; 613-225-2782; 261-492-3532-9726; 6; 5; 4; 3; 2; 60; 1; 38092-22583;

D O I：

10.1200/JCO.2023.41.6_suppl.TPS282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS282

引用

页码：TPS282 / TPS282

页数：1

共 50 条

[1] A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
Calvo, Mariona
Penkov, Konstantin
Spira, Alexander I.
Candilejo, Irene Moreno
Shore, Neal D.
Zhang, Tian
Mellado-Gonzalez, Begona
Gordoa, Teresa Alonso
Rodriguez, Luis Paz-Ares
Tarantolo, Stefano R.
Soto, Juan Jose
Alter, Robert S.
Andreu-Vieyra, Claudia
Bowler, Timothy
Maity, Arnab K.
Hariharan, Subramanian
Schweizer, Michael Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[2] Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
Schweizer, Michael Thomas
Penkov, Konstantin
Choudhury, Atish Dipankar
Calvo, Emiliano
Frank, Richard C.
Liu, Li
Mittapalli, Rajendar K.
Tougias, Jessica
Andreu-Vieyra, Claudia
Bowler, Timothy Geoffrey
Soman, Neelesh
Garmezy, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
Schweizer, M.
Penkov, K. D.
Tolcher, A. W.
Choudhury, A. D.
Doronin, V.
Aljumaily, R.
Calvo, E.
Frank, R. C.
Hamm, J. T.
Garcia, V. Moreno
Vorobyev, V.
Billotte, S.
Bowler, T.
Chen, J.
Lin, T.
Liu, L.
Maity, A.
Sharma, S.
Johnson, M. L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S763 - S764
[4] Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer
Bai, Yunfeng
Zhang, Zhuangzhuang
Cheng, Lijun
Wang, Ruixin
Chen, Xiaoliang
Kong, Yifan
Feng, Feng
Ahmad, Nihal
Li, Lang
Liu, Xiaoqi
JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (25) : 9911 - 9923
[5] Discovery of a novel class of potent, selective, and orally bioavailable histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) inhibitors and the identification of development candidate PF-06821497
Kung, Pei-Pei
Bergqvist, Simon
Bingham, Patrick
Braganza, John
Brooun, Alexei
Collins, Michael
Diehl, Wade
Deng, Ya-Li
Dinh, Dac
Fan, Connie
Fantin, Valeria
Gukasyan, Hovhannes
Hu, Wenyue
Huang, Buwen
Kania, Robert
Liu, Wei
Kephart, Susan
Kraus, Manfred
Krivacic, Cody
Kumpf, Robert
Li, Gary
Maegley, Karen
McAlpine, Indrawan
Nguyen, Lisa
Ninkovic, Sacha
Ornelas, Martha
Richter, Dan
Rui, Eugene
Ryskin, Michael
Scales, Stephanie
Spangler, Jillian
Stewart, Al
Sutton, Scott
Tatlock, John
Tsao, Cheng-Chung
Verhelle, Dominique
Wang, Fen
Wang, Hui
Wells, Peter
Wythes, Martin
Yamazaki, Shinji
Yip, Brian
Yu, Xiu
Zehnder, Luke
Zhang, Wei-Guo
Zhu, Peter
Zhu, Jinjiang
Rollins, Robert
Sharma, Shikhar
Edwards, Martin
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[6] Enhancer of zeste-homolog 2 (EZH2) expression and clinical outcomes in metastatic castrate resistant prostate cancer (mCRPC).
Giridhar, Karthik
Costello, Brian Addis
Sosa, Carlos
Huang, Haojie
Kohli, Manish
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[7] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Sharp, Adam
Bernard-Tessier, Alice
Borchiellini, Delphine
de Bono, Johann
Fizazi, Karim
Gravis, Gwenaelle
Lorente, David
Mahammedi, Hakim
Mellado, Begona
Olmos, David
Pacey, Simon
Piulats, Jose
Ramirez, Sara P.
Gorbatchevsky, Igor
Heath, Elisabeth
CANCER RESEARCH, 2024, 84 (07)
[8] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Heath, Elisabeth I.
Sharp, Adam
Borchiellini, Delphine
De Bono, Johann S.
Fizazi, Karim
Gravis, Gwenaelle
Lorente, David
Mahammedi, Hakim
Mellado-Gonzalez, Bego Na
Olmos, David
Pacey, Simon
Piulats, Josep M.
Ramirez, Sara Perez
Gorbatchevsky, Igor
Bernard-Tessier, Alice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Hauke, Ralph J.
Call, Justin A.
Sun, Jichao
Casey, Denise
Wei, Xiao X.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS242 - TPS242
[10] MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY
Neeraj, Agarwal
Michael, T. Schweizer
Elena, Castro
Arun, A. Azad
Daniel, J. George
Jayeta, Chakrabarti
Sujata, Narayanan
Yiyun, Tang
Karim, Fizazi
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)

← 1 2 3 4 5 →